Share Name Share Symbol Market Type Share ISIN Share Description
Block Commodities Ltd NEX:BLCC NEX Ordinary Share GG00B4QYTJ50
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 0.008 0.007 0.009 0.008 0.0077 0.008 64,805,844 16:30:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - -

Block Commodities strengthens its Scientific Advisory Team ('SAT') with two key appointments

09/01/2020 7:00am

UK Regulatory (RNS & others)


 
 Block Commodities Ltd (BLCC) 
Block Commodities strengthens its Scientific Advisory Team ('SAT') with two 
key appointments 
 
09-Jan-2020 / 07:00 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
 
     The information communicated within this announcement is deemed to 
     constitute inside information as stipulated under the Market Abuse 
 Regulations (EU) No. 596/2014. Upon the publication of this announcement, 
   this inside information is now considered to be in the public domain. 
 
9 January 2020 
 
       BLOCK COMMODITIES LIMITED 
 
       ("Block Commodities" or the "Company") 
 
       Block Commodities Limited / Epic: BLCC / Sector: Mining 
 
Block Commodities strengthens its Scientific Advisory Team ("SAT") with two 
       key appointments 
 
          London, 9 January 2020 - Block Commodities Ltd today announces the 
appointments of Professor Justin Stebbing and Professor Andrew Garner to its 
   Scientific Advisory Team (SAT). Professor Stebbing joins the SAT as Chair 
    and will play a central role in helping the Board to identify and unlock 
suitable investment opportunities in the CBD wellness and medicinal cannabis 
market. The SAT is further strengthened by the appointment of Professor Andy 
 Garner, who joins as a highly respected pharmaceutical and medical research 
      expert. Together with the existing members, Dr. Frank Ambrosio and Dr. 
 Olusola Idowu, the SAT is working with partners to develop pilot studies to 
        establish the efficacy of proprietary compounds treating a number of 
               conditions. 
 
       Professor Stebbing is a Professor of Cancer Medicine and Oncology and 
       Consultant Oncologist at Imperial College London, specialising in the 
      treatment of cancer by immunotherapy. Professor Stebbing brings to the 
   position relevant board experience from his current roles as Chair of the 
 World Vaccine Congress and the Irish Cancer Society oversight committee. He 
       is a Fellow of the Royal College of Physicians, the American Board of 
 Internal Medicine and the Royal College of Pathologists. Furthermore, he is 
   a published author of world leading medicine and cancer journals, such as 
The Journal of Clinical Oncology and The Lancet Oncology. He was awarded the 
    Silvia Lawler prize for excellence in oncology in 2015 and has extensive 
  clinical practice experience, including translational research studies and 
immunotherapy trials, most recently undertaking biosimilar studies. In 2016, 
he was internationally recognised with his appointment as Editor-in-Chief of 
    Oncogene (Springer Nature's foremost cancer journal) and election to the 
               American Society for Clinical Investigation. 
 
    Professor Andrew Garner has held senior positions at universities in the 
 United Kingdom, Europe, USA and the Middle East, as well as executive posts 
 in the National Health Service and the pharmaceutical industry. In 2007, he 
   was appointed as Dean and PVC at Keele University to develop and lead the 
 Faculty of Medicine & Health Sciences including new schools of Medicine and 
         Pharmacy together with Research Institutes focused on Primary Care, 
   Secondary Care and Laboratory Medicine. As a pharmacologist, he joins the 
  SAT with extensive research and consultancy experience in drug development 
      including 9 years as Company Senior Scientist with AstraZeneca. He was 
      previously NHS R&D Director for Greater Manchester, Head of Manchester 
     Medical School and a member of the Boards of the University Hospital of 
           North Midlands and West Midlands Academic Health Science Network. 
 
     With the addition of Professors Stebbing and Garner, Block Commodities' 
 management is confident that it has assembled a world-class team of experts 
  in evaluation and development of medicines and the application of cannabis 
for health and wellness. Block Commodities aims to be a market leader in CBD 
 research and cultivation, as well as a manufacturer of efficacious products 
               of the highest consistency and quality. 
 
        Ian Tordoff, Chief Executive Officer of Block Commodities commented: 
           "Following the Company's General Meeting on 27 December 2019, the 
 shareholders approved a new investment strategy to operate in the medicinal 
cannabis, CBD wellness and hemp sectors. I am delighted to welcome Professor 
Stebbing and Professor Garner to our Scientific Advisory Team to develop and 
 drive Block's ambitions in these markets. We aim to create OTC products for 
consumers who want access to the highest quality CBD products appropriate to 
 their circumstances. The SAT is essential to the business in the shaping of 
   research and product development, which underpin our commercial goals. We 
  are all looking forward to working closely together in the coming months." 
 
       ENDS 
 
CONTACTS 
 
Block Commodities Limited 
Chris Cleverly                     info@blockcommodities.com 
 
Ian Tordoff                        info@blockcommodities.com 
 
Press contact 
 
Hawthorn Advisors                  block@hawthornadvisors.com 
 
                                   +44 (0)20 3745 4960 
 
NEX Exchange Corporate Adviser: 
Alexander David Securities Limited 
David Scott - Corporate Finance    +44 (0) 20 7448 9820 
James Dewhurst - Corporate Broking +44 (0) 20 7448 9820 
 
The Directors of the Company accept responsibility for the content of this 
announcement. 
 
      Building on well-established connections and technology expertise, the 
     Company has expanded its operations into the CBD wellness and medicinal 
       cannabis market with a strategy to produce and process cannabis-based 
    products via licences in Africa, to supply the growing demand in Europe. 
 
            For more information, visit: http://www.blockcommodities.com [1] 
 
ISIN:          GG00B4QYTJ50 
Category Code: MSCM 
TIDM:          BLCC 
LEI Code:      2138001KNTXRAZTFKU51 
Sequence No.:  39435 
EQS News ID:   949599 
 
End of Announcement EQS News Service 
 
 
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=5fd957859089143ab1da9a8d39238f92&application_id=949599&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

January 09, 2020 02:00 ET (07:00 GMT)

1 Year Block Commodities Chart

1 Year Block Commodities Chart

1 Month Block Commodities Chart

1 Month Block Commodities Chart
Your Recent History
NEX
BLCC
Block Comm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200219 04:30:01